Loading...
Remdesivir (RDV) was recently granted Emergency Use Authorization for patients with severe COVID-19 based on studies showing that time to recovery was decreased with RDV versus placebo (NEJM JW Infect Dis Aug 2020 and N Engl J Med 2020 May 22; [e-pub]) and that a 5-day course was equivalent to a 10-day course in patients who were hypoxic but not mechanically ventilated (NEJM JW Infect Dis Aug 2020 and N Engl J Med 2020 May 27; [e-pub]).
Now, investigators have conducted an industry-sponsored, open-label study to evaluate the efficacy of RDV in 584 patients with moderate disease, defined as those hospitalized with evidence of COVID-19 pneumonia but no hypoxia. Patients were randomized 1:1:1 to receive 10 days of RDV, 5 days of RDV, or standar…